Lorlatinib: a new-generation drug for ALK-positive NSCLC.

Article Details

Citation

Copy to clipboard

Waqar SN, Morgensztern D

Lorlatinib: a new-generation drug for ALK-positive NSCLC.

Lancet Oncol. 2018 Dec;19(12):1555-1557. doi: 10.1016/S1470-2045(18)30789-7. Epub 2018 Nov 6.

PubMed ID

30413381 [ View in PubMed

]

Abstract

Not Available

DrugBank Data that Cites this Article

Drugs

Lorlatinib